New drugs in prostate cancer

Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136, E359, 10.1002/ijc.29210 Ross, 2008, Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect, Cancer, 112, 1247, 10.1002/cncr.23304 Egan, 2014, Castration-resistant prostate cancer: adaptive responses in the androgen axis, Cancer Treat Rev, 40, 426, 10.1016/j.ctrv.2013.09.011 Wright, 2011, Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes, Cancer Epidemiol Biomarkers Prev, 20, 619, 10.1158/1055-9965.EPI-10-1023 Yang, 2011, SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer, J Clin Oncol, 29, 2565, 10.1200/JCO.2010.31.2405 Stanbrough, 2006, Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer, Cancer Res, 66, 2815, 10.1158/0008-5472.CAN-05-4000 Ford, 2003, Androgen receptor gene amplification and protein expression in recurrent prostate cancer, J Urol, 170, 1817 Hay, 2012, The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity, PLoS One, 7, e32514, 10.1371/journal.pone.0032514 Sun, 2010, Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant, J Clin Invest, 120, 2715, 10.1172/JCI41824 Heemers, 2007, Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex, Endocr Rev, 28, 778, 10.1210/er.2007-0019 Arora, 2013, Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade, Cell, 155, 1309, 10.1016/j.cell.2013.11.012 Grasso, 2012, The mutational landscape of lethal castration-resistant prostate cancer, Nature, 487, 239, 10.1038/nature11125 Saad, 2015, Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial, Lancet Oncol, 16, 338, 10.1016/S1470-2045(15)70027-6 Toren, 2015, Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer, Mol Cancer Ther, 14, 59, 10.1158/1535-7163.MCT-14-0521 Montgomery, 2016, Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II studies: galeterone for the treatment of castration-resistant prostate cancer, Clin Cancer Res, 22, 1356, 10.1158/1078-0432.CCR-15-1432 Loriot, 2014, Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study, Invest New Drugs, 32, 995, 10.1007/s10637-014-0101-x Fizazi, 2014, Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial, Lancet Oncol, 15, 975, 10.1016/S1470-2045(14)70240-2 Omlin, 2015, AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer—results of two parallel first-in-human phase I studies, Invest New Drugs, 33, 679, 10.1007/s10637-015-0235-5 Brand, 2015, EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer, Oncotarget, 6, 3811, 10.18632/oncotarget.2924 Maughan, 2015, Clinical relevance of androgen receptor splice variants in castration-resistant prostate cancer, Curr Treat Options Oncol, 16, 57, 10.1007/s11864-015-0375-z Ross, 2008, A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel, Cancer, 112, 521, 10.1002/cncr.23195 Fury, 2012, A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors, Cancer Chemother Pharmacol, 69, 591, 10.1007/s00280-011-1734-5 Vaishampayan, 2015, Phase II trial of carboplatin, everolimus, and prednisone in metastatic castration-resistant prostate cancer pretreated with docetaxel chemotherapy: a Prostate Cancer Clinical Trial Consortium study, Urology, 86, 1206, 10.1016/j.urology.2015.08.008 Pili, 2011, Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer, J Clin Oncol, 29, 4022, 10.1200/JCO.2011.35.6295 Kim, 2009, Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis, Cancer Res, 69, 700, 10.1158/0008-5472.CAN-08-3157 Tomlinson, 2015, Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced malignant solid tumors, Clin Cancer Res, 21, 2480, 10.1158/1078-0432.CCR-14-2610 Falchook, 2016, Effect of food on the pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors, Drugs R D, 16, 45, 10.1007/s40268-015-0114-8 Beltran, 2011, Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets, Cancer Discov, 1, 487, 10.1158/2159-8290.CD-11-0130 Sowery, 2008, Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy, BJU Int, 102, 389, 10.1111/j.1464-410X.2008.07618.x Chi, 2010, Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer, J Clin Oncol, 28, 4247, 10.1200/JCO.2009.26.8771 Gravina, 2015, KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and surviving in prostate cancer models, BMC Cancer, 15, 941, 10.1186/s12885-015-1936-z Lamoureux, 2013, Dual inhibition of autophagy and the AKT pathway in prostate cancer, Autophagy, 9, 1119, 10.4161/auto.24921 Smith, 2013, Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial, J Clin Oncol, 31, 412, 10.1200/JCO.2012.45.0494 Chow, 2016, A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer, Cancer, 122, 1897, 10.1002/cncr.29927 2014, Dovitinib reduces prostate cancer bone metastases, Cancer Discov, 4, OF3, 10.1158/2159-8290.CD-NB2014-145 Fenoglio, 2013, A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer, Cancer Immunol Immunother, 62, 1041, 10.1007/s00262-013-1415-9 Kantoff, 2010, Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer, J Clin Oncol, 28, 1099, 10.1200/JCO.2009.25.0597 McNeel, 2015, Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: a trial of the ECOG-ACRIN cancer research group (E1809), Hum Vaccin Immunother, 11, 2469, 10.1080/21645515.2015.1062190 Podrazil, 2015, Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer, Oncotarget, 6, 18192, 10.18632/oncotarget.4145 Chakraborty, 2003, Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy, J Immunol, 170, 6338, 10.4049/jimmunol.170.12.6338 Slovin, 2013, Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study, Ann Oncol, 24, 1813, 10.1093/annonc/mdt107 Kwon, 2014, Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial, Lancet Oncol, 15, 700, 10.1016/S1470-2045(14)70189-5 DiPippo, 2015, Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts, Prostate, 75, 303, 10.1002/pros.22916 Mateo, 2015, DNA-repair defects and olaparib in metastatic prostate cancer, N Engl J Med, 373, 1697, 10.1056/NEJMoa1506859